Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073164 · ClinicalTrials.gov registry record · Phase 2
Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00073164 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 400 participants.
The verdict
NCT00073164, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the 14-day and 12-week safety and efficacy of Depakote ER used in combination with either olanzapine or risperidone versus antipsychotic monotherapy with olanzapine or risperidone for the treatment of schizophrenia.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Divalproex Sodium Extended-Release Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073164
The ClinicalTrials.gov registry entry for NCT00073164 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Risperidone is the first listed.
NCT00073164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073164 about?
NCT00073164 is a clinical study titled "Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia". The purpose of this study is to assess the 14-day and 12-week safety and efficacy of Depakote ER used in combination with either olanzapine or risperidone versus antipsychotic monotherapy with olanzapine or risperidone for the treatment of schizophrenia.
What is the current status of trial NCT00073164?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00073164?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Divalproex Sodium Extended-Release Tablets (DRUG).
Who is sponsoring clinical trial NCT00073164?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.